GANX240517P5000
- 1.25
- 0.000.00%
Gain Therapeutics Newsroom
Buy Rating Affirmed for Gain Therapeutics Amidst Promising Clinical Trials and Strong Financial Health
Buy Rating Affirmed for Gain Therapeutics Amid Positive Clinical and Financial Performance
Gain Therapeutics | 10-Q: Quarterly report
Express News | Gain Therapeutics' Q1 Cash, Cash Equivalent And Marketable Securities Were $12.7M, With Cash Runway Guidance Into 2025
Gain Therapeutics 1Q Loss $4.01M >GANX
Gain Therapeutics 1Q Loss $4.01M >GANX
Express News | Gain Therapeutics Inc - Reiterating Cash Runway Guidance Into 2025
Express News | Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Express News | Gain Therapeutics Q1 EPS USD -0.22
Buy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progress
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)
Gain Therapeutics Shares Rise 8% After Positive Results From Early Trial of Parkinson's Disease Therapy
By Chris Wack Gain Therapeutics shares rose after the company said it saw positive results from an early study of its potential Parkinson's Disease therapy. Shares were up 8% to $3.65 in early tradi
Express News | Gain Therapeutics Announces Positive Results From the Single Ascending Dose (Sad) Part of the Phase 1 Clinical Trial of GT-02287, a Novel Gcase-Targeting Small Molecule Therapy for Gba1 Parkinson’s Disease
Express News | Oppenheimer Maintains Outperform on Gain Therapeutics, Maintains $9 Price Target
Oppenheimer Remains a Buy on Gain Therapeutics (GANX)
Here's Why Gain Therapeutics (GANX) Could Be Great Choice for a Bottom Fisher
Insiders Are Piling Into These 10 Healthcare Stocks in 2024
Gain Therapeutics Welcomes New CFO Gene Mack
Express News | Gain Therapeutics Appoints Gene Mack As CFO
Gain Therapeutics Appoints Gene Mack as Chief Financial Officer >GANX
Gain Therapeutics Appoints Gene Mack as Chief Financial Officer >GANX
Gain Therapeutics Bolsters Management Team With the Appointment of Gene Mack as Chief Financial Officer
Gain Therapeutics, Inc. (Nasdaq: GANX) today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.